Thomas W. Beetham
CIK 1741382 · Chief Operating Officer · last filed 2026-03-09
Thomas W. Beetham is a Chief Operating Officer who has filed 26 SEC Form 4 insider transactions across 3 companies since 2018. The most recent filing shows the insider had shares withheld for taxes covering $92.0K of VRDN on Mar 9, 2026. Across all open-market trades the lifetime net is −$2.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $15.8M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$15.79M
3
26
-$2.03M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VRDN | Chief Operating Officer | 13,361 | $16.35 | $218.5K | $117.0K | 5 | 2026-03-09 |
| Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | See Remarks | 19,897 | $11.19 | $222.7K | -$41.1K | 8 | 2022-12-02 |
| KNSA | EVP & Chief Legal Officer | 300,000 | $51.89 | $15.57M | -$2.11M | 13 | 2021-03-23 |
Recent Filings
26 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-03-09 | VRDN | Tax (F) | −3,048 | -$92.0K | EDGAR |
| 2026-03-04 | VRDN | Mixed | +6,271 | -$92.0K | EDGAR |
| 2025-03-04 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2024-09-30 | VRDN | Buy (P) | +5,000 | $117.0K | EDGAR |
| 2023-11-01 | VRDN | Grant (A) | — | $0 | EDGAR |
| 2022-12-02 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | +3,000 | $2.8K | EDGAR |
| 2022-08-01 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-06 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | +3,000 | $3.0K | EDGAR |
| 2022-05-19 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-02-17 | Dianthus Therapeutics, Inc. /DE/ (MGTA) Delisted | Grant (A) | — | $0 | EDGAR |